UT leads new project to explore the mysteries of brain connections – News-Medical.net

Reviewed by Emily Henderson, B.Sc.Aug 19 2020

Researchers at The University of Texas at Austin will lead an ambitious new project with 10 other U.S. institutions and global partners that has significant implications for understanding human brain health.

With support from the Next Generation Networks for Neuroscience (NeuroNex) program at the National Science Foundation (NSF), the team will examine newly discovered complexities related to synapses -- the tiny structures that form trillions of connections between nerve cells in the brain and allow us to think, sense, learn, act and remember. The partnership, which includes scientists in Germany, the United Kingdom and Canada, hopes to explore new ways to define what determines the strength of synapses and what alters their strength.

Traditionally, synapses have been treated as on or off switches -- essentially, 1-bit machines -- but this assumption is wrong. Our team discovered that the information content stored in the size of a synapse can be much higher, already found to be greater than 4 bits in some brain regions. What this outcome means is that synapses are less like light switches and more like dimmer switches that can dial in the desired strength depending on need or mood."

Kristen Harris, professor in the UT Department of Neuroscience and the Center for Learning and Memory, project leader

Because new research has found synapses to be far more varied and nuanced than neuroscientists believed five years ago, the new project will examine many aspects of what's known as synaptic weight (or strength). The international scientific team will explore variation among synapses, from the level of molecules to the level of circuits, to determine what differences among them mean for our basic understanding of the brain.

Using multidisciplinary approaches, cutting-edge imaging technologies and cyber resources, the research team will generate data to predict how specific neural circuits form and function. Because recent research has uncovered the important role of differences in synaptic strength, the new project will explore how factors such as size, connectivity, volume, cellular resources and protein composition help shape these nanometer-sized structures and the effects that these differences have in the brain.

"There's still so much we don't know about how the brain works, and one of the keys to unlocking those mysteries is finding out more about specific neural circuits," said NSF NeuroNex Program Director Floh Thiels. "This requires bringing together researchers from fields including chemistry, biology and computer science and engineering, and applying the latest analysis techniques to the data they produce. This has been a goal for neuroscientists for years, and what we will see from this network of researchers is a new chapter of international collaboration and coordination."

To compare and map synaptic weights the team is developing a new form of electron microscopy called tomoSEM (tomographic scanning electron microscopy), which will be able to capture information in high resolution and across large field sizes as necessary for the research. Once completed in the Harris lab, tomoSEM will be implemented and tested across labs in this NeuroNex network, and ultimately it will be standardized for general use. The images and tools will be shared with the scientific community on a public website in collaboration with UT's Texas Advanced Computing Center (TACC).

NSF has awarded more than $50 million over five years to four interdisciplinary teams, including $17.5 million for the U.S. component of the team Harris is leading. Collaborators are Alice Ting at Stanford University; Mark Ellisman at the University of California, San Diego; Erik Jorgenson and Bryan Jones the University of Utah; Clay Reid at the Allen Institute for Brain Science; Davi Bock at the University of Vermont; Narayanan Kasthuri at the University of Chicago; Linnaea Ostroff at the University of Connecticut at Storrs; Terrence Sejnowski and Uri Manor at the Salk Institute for Biological Studies; Joshua Vogelstein at Johns Hopkins University; and James Carson at TACC. In addition, Viren Jain at Google (US) will participate in this project.

Originally posted here:
UT leads new project to explore the mysteries of brain connections - News-Medical.net

New treatment increases the speed of nerve regeneration for trauma patients – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.Aug 19 2020

A University of Alberta researcher has found a treatment that increases the speed of nerve regeneration by three to five times, leading to much better outcomes for trauma surgery patients.

We use the term 'time is muscle. If that regrowing nerve can't get to the muscle fast enough, you're not going to get a functional repair."

Christine Webber, associate professor in the U of A's anatomy division and a member of the Neuroscience and Mental Health Institute

Peripheral nerve injury occurs in about three per cent of trauma victims. The slow nature of nerve regeneration means that often muscles atrophy before the nerve has a chance to grow and reconnect.

That's where conditioning electrical stimulation (CES) comes in.

Webber and her collaborators--plastic surgery resident and former PhD student Jenna-Lynn Senger, and physical rehabilitation clinician Ming Chan--have examined CES in many previous publications. The process involves electrically stimulating a nerve at the fairly low rate of 20 hertz for one hour. A week after the CES treatment, nerve surgery is done, and the nerves grow back three to five times faster than if the surgery was done without CES.

In their latest work on CES, Webber's group examined animal models with foot drop, a common injury that affects patients' quality of life by impeding their ability to walk normally. Previously, the only treatments for foot drop were orthotics that affect a patient's gait, or surgery.

Webber's lab performed a distal nerve transfer in which a nerve near the damaged one was electrically stimulated, then a week later a branch of the nerve was cut and placed near the target of the non-functioning nerve. The newly transferred nerve would then be primed and ready to regrow, at a much faster rate, into the muscles that lift the foot.

CES can be a tool for faster nerve regrowth in any portion of the peripheral nervous system. Ming Chan, also a Neuroscience and Mental Health Institute member, has started a clinical trial in which CES is used before a nerve repair of the carpal tunnel.

Webber hopes to bring the information gained from examining nerve transfers in the leg--a difficult body part for nerve regrowth due to the vast area the nerve must cover--to clinical trials within the next year or two.

Source:

Journal reference:

Senger, J.B., et al. (2020) Conditioning Electrical Stimulation Accelerates Regeneration in Nerve Transfers. Annals of Neurology. doi.org/10.1002/ana.25796.

Original post:
New treatment increases the speed of nerve regeneration for trauma patients - News-Medical.Net

Merck to build 1B London R&D hub for its first ex-U.S. early research center – FierceBiotech

Making good on its 2017 promise to back post-Brexit Britain, U.S. Big Pharma Merck is set to spend 1 billion ($1.31 billion) on a new unifying early research hub in Englands capital city.

The new hub, which will bring together staffers from across the region to a central hub in London, will be the company's first early-stage R&D center outside of its native U.S. The focus will be on diseases of aging, predominately in neuroscience, an area with high risk but major unmet need.

Merck had made moves to create the hub back in 2017, a year after the U.K. voted to leave the EU, and was hailed by politicians as a positive investment.

Humanized Mouse Models for Drug Discovery: The NOG Portfolio

Human immune system mouse models are leading to breakthroughs in a wide range of research applications. In this white paper, explore the NOG portfolio and the unique benefits of each model to determine the appropriate choice for your study.

It has been somewhat delayed, given how tight space is in London (the same issues New York has with lab space) and it wanting to be in the life sciences hub by the Francis Crick biomedical research institute in north London. Merck, known as MSD in Europe, already has a major five-year neuro R&D pact with the Crick Institute.

It will be called, quite simply, the London Discovery Research Centre, and it should be up and running by 2025, with work starting late next year, should it cut through the red tape. On top of the moving scientists and staffers from its other areas into the center, it also expects to create about 120 new jobs for scientists and technicians.

In all, it expects to employ 800 people at the 25,000-square-metersiteand to spend 1 billion all told on the hub.

We currently view the U.K. as a world leader in developing science, driven by the long-term emphasis on building a strong research and development infrastructure, said David Peacock, MSD managing director for the U.K. and Ireland, speaking to the Financial Times.

View post:
Merck to build 1B London R&D hub for its first ex-U.S. early research center - FierceBiotech

Researchers solve a long-held mystery of X chromosome inactivation – News-Medical.net

Researchers at Massachusetts General Hospital (MGH) have solved a mystery that has long puzzled scientists: How do the bodies of female humans and all other mammals decide which of the two X chromosomes it carries in each cell should be active and which one should be silent?

In a breakthrough study published in Nature Cell Biology, the MGH team discovered the role of a critical enzyme in the phenomenon known as X chromosome inactivation (XCI), which is essential for normal female development and also sets the stage for genetic disorders known as X-linked diseases (such as Rett Syndrome) to occur.

Scientists have known for over a half-century that female mammals undergo XCI during embryo formation. Females have two copies of the X chromosome, and each carries many genes.

Having genes expressed on both X chromosomes would be toxic to the cell, as would having both X chromosomes inactivated. To avoid these fates, females evolved with a mechanism that inactivates, or silences, one of the chromosomes.

Over the years, investigators have made strides in understanding how XCI occurs. In 2006, a team led by Jeannie Lee, MD, PhD, of the Department of Molecular Biology at MGH reported that during embryo development the two X chromosomes briefly come together, or pair.

She and her colleagues have since uncovered conclusive evidence that pairing is necessary for the body to decide which X chromosome to inactivate. "But until now, no one knew what one X chromosome was saying to the other to make the decision," says Lee, who is senior author of the Nature Cell Biology paper.

To find out, Lee and her colleagues had to develop sophisticated molecular tools that allow them to study key proteins involved in XCI, which were previously difficult to measure. It was already known that, prior to pairing, both X chromosomes are identical, or "symmetrical," meaning that they express the same genes.

Importantly, both express a form of noncoding RNA called Xist, which plays a vital role in inactivating the X chromosome. However, both X chromosomes also express another form of RNA, Tsix, which blocks Xist and prevents XCI.

In the Nature Cell Biology paper, Lee and her team show that an enzyme called DCP1A randomly chooses one X chromosome to bind to, and in doing so it cuts off, or "decaps," Tsix's protective cover, making the RNA unstable. However, because DCP1A exists in tiny quantities, there is only enough to bind to one X chromosome. "DCP1A flips the switch that starts the entire cascade of X chromosome inactivation," says Lee.

As a result, a protein called CTCF--the "glue" that holds X chromosomes together during pairing--binds to the unstable Tsix RNA and causes it to shut down permanently. Xist is then able to complete the silencing of that X chromosome.

DCP1A allows the two X chromosomes to have a fateful 'conversation', noting that there are many other instances where the body must choose which copy of a gene to express in order to maintain a healthy state. "This discovery, will help scientists understand how other molecular conversations take place in the cell."

Jeannie Lee, MD, PhD, Professor and Director, Department of Molecular Biology, Massachusetts General Hospital

Jeannie Lee, MD, Ph.D., of the Department of Molecular Biology at MGH, is also director of the Lee Laboratory and a professor of Genetics at Harvard Medical School.

Source:

Journal reference:

Aeby, E., et al. (2020) Decapping enzyme 1A breaks X-chromosome symmetry by controlling Tsix elongation and RNA turnover. Nature Cell Biology. doi.org/10.1038/s41556-020-0558-0.

Go here to read the rest:
Researchers solve a long-held mystery of X chromosome inactivation - News-Medical.net

Researchers find method to regrow cartilage in the joints – Stanford Medical Center Report

Damaged cartilage can be treated through a technique called microfracture, in which tiny holes are drilled in the surface of a joint. The microfracture technique prompts the body to create new tissue in the joint, but the new tissue is not much like cartilage.

Microfracture results in what is called fibrocartilage, which is really more like scar tissue than natural cartilage, said Chan. It covers the bone and is better than nothing, but it doesnt have the bounce and elasticity of natural cartilage, and it tends to degrade relatively quickly.

The most recent research arose, in part, through the work of surgeon Matthew Murphy, PhD, a visiting researcher at Stanford who is now at the University of Manchester. I never felt anyone really understood how microfracture really worked, Murphy said. I realized the only way to understand the process was to look at what stem cells are doing after microfracture. Murphy is the lead author on the paper. Chan and Longaker are co-senior authors.

For a long time, Chan said, people assumed that adult cartilage did not regenerate after injury because the tissue did not have many skeletal stem cells that could be activated. Working in a mouse model, the team documented that microfracture did activate skeletal stem cells. Left to their own devices, however, those activated skeletal stem cells regenerated fibrocartilage in the joint.

But what if the healing process after microfracture could be steered toward development of cartilage and away from fibrocartilage? The researchers knew that as bone develops, cells must first go through a cartilage stage before turning into bone. They had the idea that they might encourage the skeletal stem cells in the joint to start along a path toward becoming bone, but stop the process at the cartilage stage.

The researchers used a powerful molecule called bone morphogenetic protein 2 (BMP2) to initiate bone formation after microfracture, but then stopped the process midway with a molecule that blocked another signaling molecule important in bone formation, called vascular endothelial growth factor (VEGF).

What we ended up with was cartilage that is made of the same sort of cells as natural cartilage with comparable mechanical properties, unlike the fibrocartilage that we usually get, Chan said. It also restored mobility to osteoarthritic mice and significantly reduced their pain.

As a proof of principle that this might also work in humans, the researchers transferred human tissue into mice that were bred to not reject the tissue, and were able to show that human skeletal stem cells could be steered toward bone development but stopped at the cartilage stage.

The next stage of research is to conduct similar experiments in larger animals before starting human clinical trials. Murphy points out that because of the difficulty in working with very small mouse joints, there might be some improvements to the system they could make as they move into relatively larger joints.

The first human clinical trials might be for people who have arthritis in their fingers and toes. We might start with small joints, and if that works we would move up to larger joints like knees, Murphy says. Right now, one of the most common surgeries for arthritis in the fingers is to have the bone at the base of the thumb taken out. In such cases we might try this to save the joint, and if it doesnt work we just take out the bone as we would have anyway. Theres a big potential for improvement, and the downside is that we would be back to where we were before.

Longaker points out that one advantage of their discovery is that the main components of a potential therapy are approved as safe and effective by the FDA. BMP2 has already been approved for helping bone heal, and VEGF inhibitors are already used as anti-cancer therapies, Longaker said. This would help speed the approval of any therapy we develop.

Joint replacement surgery has revolutionized how doctors treat arthritis and is very common: By age 80, 1 in 10 people will have a hip replacement and 1 in 20 will have a knee replaced. But such joint replacement is extremely invasive, has a limited lifespan and is performed only after arthritis hits and patients endure lasting pain. The researchers say they can envision a time when people are able to avoid getting arthritis in the first place by rejuvenating their cartilage in their joints before it is badly degraded.

One idea is to follow a Jiffy Lube model of cartilage replenishment, Longaker said. You dont wait for damage to accumulate you go in periodically and use this technique to boost your articular cartilage before you have a problem.

Longaker is the Deane P. and Louise Mitchell Professor in the School of Medicine and co-director of the Institute for Stem Cell Biology and Regenerative Medicine. Chan is a member of the Institute for Stem Cell Biology and Regenerative Medicine and Stanford Immunology.

Other Stanford scientist taking part in the research were professor of pathology Irving Weissman, MD, the Virginia and D. K. Ludwig Professor in Clinical Investigation in Cancer Research; professor of surgery Stuart B. Goodman, MD, the Robert L. and Mary Ellenburg Professor in Surgery; associate professor of orthopaedic surgery Fan Yang, PhD; professor of surgery Derrick C. Wan, MD; instructor in orthopaedic surgery Xinming Tong, PhD; postdoctoral research fellow Thomas H. Ambrosi, PhD; visiting postdoctoral scholar Liming Zhao, MD; life science research professionals Lauren S. Koepke and Holly Steininger; MD/PhD student Gunsagar S. Gulati, PhD; graduate student Malachia Y. Hoover; former student Owen Marecic; former medical student Yuting Wang, MD; and scanning probe microscopy laboratory manager Marcin P. Walkiewicz, PhD.

The research was supported by the National Institutes of Health (grants R00AG049958, R01 DE027323, R56 DE025597, R01 DE026730, R01 DE021683, R21 DE024230, U01HL099776, U24DE026914, R21 DE019274, NIGMS K08GM109105, NIH R01GM123069 and NIH1R01AR071379), the California Institute for Regenerative Medicine, the Oak Foundation, the Pitch Johnson Fund, the Gunn/Olivier Research Fund, the Stinehart/Reed Foundation, The Siebel Foundation, the Howard Hughes Medical Institute, the German Research Foundation, the PSRF National Endowment, National Center for Research Resources, the Prostate Cancer Research Foundation, the American Federation of Aging Research and the Arthritis National Research Foundation.

More here:
Researchers find method to regrow cartilage in the joints - Stanford Medical Center Report

How We Could Control Cells in the Body to Treat Conditions – Lab Manager Magazine

WASHINGTON, DC Like electronic devices, biological cells send and receive messages, but they communicate through very different mechanisms. Now, scientists report progress on tiny communication networks that overcome this language barrier, allowing electronics to eavesdrop on cells and alter their behaviorand vice versa. These systems could enable applications including a wearable device that could diagnose and treat a bacterial infection or a capsule that could be swallowed to track blood sugar and make insulin when needed.

The researchers will present their results today at the American Chemical Society (ACS) Fall 2020 Virtual Meeting & Expo. ACS is holding the meeting through Thursday. It features more than 6,000 presentations on a wide range of science topics.

"We want to expand electronic information processing to include biology," says principal investigator William E. Bentley, PhD. "Our goal is to incorporate biological cells in the computational decision-making process."

The new technology Bentley's team developed relies on redox mediators, which move electrons around cells. These small molecules carry out cellular activities by accepting or giving up electrons through reduction or oxidation reactions. Because they can also exchange electrons with electrodes, thereby producing a current, redox mediators can bridge the gap between hardware and living tissue. In ongoing work, the team, which includes co-principal investigator Gregory F. Payne, PhD, is developing interfaces to enable this information exchange, opening the way for electronic control of cellular behavior, as well as cellular feedback that could operate electronics.

"In one project that we are reporting on at the meeting, we engineered cells to receive electronically generated information and transmit it as molecular cues," says Eric VanArsdale, a graduate student in Bentley's lab at the University of Maryland, who is presenting the latest results at the meeting. The cells were designed to detect and respond to hydrogen peroxide. When placed near a charged electrode that generated this redox mediator, the cells produced a corresponding amount of a quorum sensing molecule that bacteria use to signal to each other and modulate behavior by altering gene expression.

In another recent project, the team engineered two types of cells to receive molecular information from the pathogenic bacteriaPseudomonas aeruginosa and convert it into an electronic signal for diagnostic and other applications. One group of cells produced the amino acid tyrosine, and another group made tyrosinase, which converts tyrosine into a molecule called L-DOPA. The cells were engineered so this redox mediator would be produced only if the bacteria released both a quorum sensing molecule and a toxin associated with a virulent stage ofP. aeruginosa growth. The size of the resulting current generated by L-DOPA indicated the amount of bacteria and toxin present in a sample. If used in a blood test, the technique could reveal an infection and also gauge its severity. Because this information would be in electronic form, it could be wirelessly transmitted to a doctor's office and a patient's cell phone to inform them about the infection, Bentley says. "Ultimately, we could engineer it so that a wearable device would be triggered to give the patient a therapeutic after an infection is detected."

The researchers envision eventually integrating the communication networks into autonomous systems in the body. For instance, a diabetes patient could swallow a capsule containing cells that monitor blood sugar. The device would store this blood sugar data and periodically send it to a cell phone, which would interpret the data and send back an electronic signal directing other cells in the capsule to make insulin as needed. As a step toward this goal, VanArsdale developed a biological analog of computer memory that uses the natural pigment melanin to store information and direct cellular signaling.

In other work, Bentley's team and collaborators including Reza Ghodssi, PhD, recently designed a system to monitor conditions inside industrial bioreactors that hold thousands of gallons of cell culture for drug production. Currently, manufacturers track oxygen levels, which are vital to cells' productivity, with a single probe in the side of each vessel. That probe can't confirm conditions are uniform everywhere in the bioreactor, so the researchers developed "smart marbles" that will circulate throughout the vessel measuring oxygen. The marbles transmit data via Bluetooth to a cell phone that could adjust operating conditions. In the future, these smart marbles could serve as a communication interface to detect chemical signals within a bioreactor, send that information to a computer, and then transmit electronic signals to direct the behavior of engineered cells in the bioreactor. The team is working with instrument makers interested in commercializing the design, which could be adapted for environmental monitoring and other uses.

- This press release was originally published on theACS website

Link:
How We Could Control Cells in the Body to Treat Conditions - Lab Manager Magazine

Loss of Enzyme Increases Metabolism and Exercise Endurance in Mice – Technology Networks

Sugars and fats are the primary fuels that power every cell, tissue and organ. For most cells, sugar is the energy source of choice, but when nutrients are scarce, such as during starvation or extreme exertion, cells will switch to breaking down fats instead.

The mechanisms for how cells rewire their metabolism in response to changes in resource availability are not yet fully understood, but new research reveals a surprising consequence when one such mechanism is turned off: an increased capacity for endurance exercise.

In a study published in Cell Metabolism, Harvard Medical School researchers identifiedacritical role oftheenzyme, prolyl hydroxylase 3 (PHD3), in sensing nutrient availability and regulating the ability of muscle cells to break down fats. When nutrients are abundant, PHD3 acts as a brake that inhibits unnecessary fat metabolism. This brake is released when fuel is low and more energy is needed, such as during exercise.

Remarkably, blocking PHD3 production in miceleadsto dramatic improvements in certain measures of fitness, the research showed. Compared with their normal littermates, mice lacking the PHD3 enzyme ran 40 percent longer and 50 percent farther on treadmills andhadhigher VO2 max, a marker of aerobic endurance that measures maximum oxygen uptake during exercise.

The findings shed light on a key mechanism for how cells metabolize fuels and offer clues toward a better understanding of muscle function and fitness, the authors said.

Our results suggest that PHD3 inhibition in whole body or skeletal muscle is beneficial for fitness in terms of endurance exercise capacity, running time and running distance, said senior study authorMarcia Haigis, professor of cell biology in the Blavatnik Institute at HMS. Understanding this pathway and how our cells metabolize energy and fuels potentially has broad applications in biology, ranging from cancer control to exercise physiology.

However, further studies are needed to elucidate whetherthis pathway canbe manipulated in humans to improve muscle function in disease settings, the authors said.

Haigis and colleagues set out to investigate the function of PHD3, an enzyme that they had found to play a role regulating fat metabolism in certaincancersin previous studies. Their work showed that, under normal conditions, PHD3 chemically modifies another enzyme, ACC2, which in turn prevents fatty acids from entering mitochondria to be broken down into energy.

In the current study, the researchers experiments revealed that PHD3 and another enzyme called AMPK simultaneously control the activity of ACC2 to regulate fat metabolism, depending on energy availability.

In isolated mouse cells grown in sugar-rich conditions, the team found that PHD3 chemically modifies ACC2 to inhibit fat metabolism. Under low-sugar conditions, however, AMPK activates and places a different, opposing chemical modification on ACC2, which represses PHD3 activity and allows fatty acids to enter the mitochondria to be broken down for energy.

These observations were confirmed in live mice that were fasted to induce energy-deficient conditions. In fasted mice, the PHD3-dependent chemical modification to ACC2 was significantly reduced in skeletal and heart muscle, compared to fed mice. By contrast, the AMPK-dependent modification to ACC2 increased.

Longer and further

Next, the researchers explored the consequences when PHD3 activity was inhibited, using genetically modified mice that do not express PHD3. Because PHD3 is most highly expressed in skeletal muscle cells and AMPK has previously been shown to increase energy expenditure and exercise tolerance, the team carried out a series of endurance exercise experiments.

The question we asked was if we knock out PHD3, Haigis said, would that increase fat burning capacity and energy production and have a beneficial effect in skeletal muscle, which relies on energy for musclefunctionand exercisecapacity?

To investigate, the team trained young, PHD3-deficient mice to run on an inclined treadmill. They found that these mice ran significantly longer and further before reaching the point of exhaustion, compared to mice with normal PHD3. These PHD3-deficient mice also had higher oxygen consumption rates, as reflected by increased VO2 and VO2 max.

Aftertheendurance exercise, the muscles of PHD3-deficient mice had increased rates of fat metabolism and an altered fatty acid composition and metabolic profile. The PHD3-dependent modification to ACC2 was nearly undetectable, but the AMPK-dependent modification increased, suggesting that changes to fat metabolism play a role in improving exercise capacity.

These observations held true in mice genetically modified to specifically prevent PHD3 production in skeletal muscle, demonstrating that PHD3 loss in muscle tissues is sufficient to boost exercise capacity, according to the authors.

It was exciting to see this big, dramatic effect on exercise capacity, which could be recapitulated with a muscle-specific PHD3 knockout, Haigis said. The effect of PHD3 loss was very robust and reproducible.

The research team also performed a series of molecular analyses to detail the precise molecular interactions that allow PHD3 to modify ACC2, as well as how its activity is repressed by AMPK.

The study results suggest a new potential approach for enhancingexercise performance by inhibiting PHD3.While the findings are intriguing, the authors note that further studies are needed to better understand precisely how blocking PHD3 causes a beneficial effect on exercise capacity.

In addition, Haigis and colleagues found in previous studies that in certain cancers, such as some forms of leukemia, mutated cells express significantly lower levels of PHD3 and consume fats to fuel aberrant growth and proliferation. Efforts to control this pathway as a potential strategy for treating such cancers may help inform research in other areas, such as muscle disorders.

It remains unclear whether there are any negative effects of PHD3 loss. To know whether PHD3 can be manipulated in humansfor performance enhancement in athletic activities or as a treatment for certain diseases will require additional studies in a variety of contexts, the authors said.

It also remains unclear if PHD3 loss triggers other changes, such as weight loss, blood sugar and other metabolic markers, which are now being explored by the team.

A better understanding of these processes and the mechanisms underlying PHD3 function could someday help unlock new applications in humans, such as novel strategies for treating muscle disorders, Haigis said.

Reference: Yoon et al. (2020).PHD3 Loss Promotes Exercise Capacity and Fat Oxidation in Skeletal Muscle. Cell Metabolism.DOI: 10.1016/j.cmet.2020.06.017.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

More:
Loss of Enzyme Increases Metabolism and Exercise Endurance in Mice - Technology Networks

Boundless Bio Announces Publication in Nature Genetics Detailing the Association Between Extrachromosomal DNA-Based Oncogene Amplification and Poor…

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio, a company developing innovative new therapies directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today announced research published in the journal Nature Genetics that demonstrates that ecDNA-based oncogene amplification drives poor outcomes for patients across many cancer types.

The manuscript, Frequent extrachromosomal oncogene amplification drives aggressive tumors, was co-authored by Boundless Bio scientists Nam-phuong Nguyen, Ph.D., and Kristen Turner, Ph.D., and scientific founders Paul Mischel, M.D., Distinguished Professor at the University of California San Diego (UC San Diego) School of Medicine and a member of the Ludwig Institute for Cancer Research; Vineet Bafna, Ph.D., Professor of Computer Science & Engineering, UC San Diego; Howard Chang, M.D., Ph.D., Virginia and D.K. Ludwig Professor of Cancer Genomics and Genetics, Stanford University; and Roel Verhaak, Ph.D., Professor and Associate Director of Computational Biology, The Jackson Laboratory.

The researchers used intensive computational analysis of whole-genome sequencing data from more than 3200 tumor samples in The Cancer Genome Atlas (TCGA) and the Pan-Cancer Analysis of Whole Genomes (PCAWG), totaling over 400 TB of raw sequencing data, to observe the impact of ecDNA amplification on patient outcomes. The researchers observed that ecDNA amplification occurs in many types of cancers, but not in normal tissue or in whole blood, and that the most common recurrent oncogene amplifications frequently arise on ecDNA. Notably, ecDNA-based circular amplicons were found in 25 of 29 cancer types analyzed, and at high frequency in many cancers that are considered to be amongst the most aggressive histological types, such as glioblastoma, sarcoma, and esophageal carcinoma. In addition, patients whose cancers carried ecDNA had significantly shorter survival, even when controlled for tissue type, than patients whose cancers were not driven by ecDNA-based oncogene amplification.

The findings demonstrate that ecDNA play a critical role in cancer, providing a mechanism for achieving and maintaining high copy number oncogene amplification and genetic heterogeneity while driving enhanced chromatin accessibility and elevating oncogene transcription. ecDNA amplifications are associated with aggressive cancer behavior, potentially by providing tumors with additional routes to circumvent current treatments and other evolutionary bottlenecks. The shorter overall survival, even when stratified by tumor type, raises the possibility that cancer patients whose tumors are driven by ecDNA may not be as responsive to current therapies and may be in need of new forms of treatment.

This important study builds on our rapidly expanding knowledge about ecDNA, showing, for the first time, that ecDNA amplifications are present in a broad range of cancer tumor types, said Jason Christiansen, Ph.D., Chief Technology Officer of Boundless Bio. These results point to the urgent need for therapies that can target ecDNA and interfere with their ability to drive aggressive cancer growth, resistance, and recurrence.

By detecting and characterizing the role that ecDNA play in driving hard-to-treat cancers, we are drawing a more accurate map of the cancer genome, said Dr. Mischel. It is our goal to take these findings and apply them to the development of powerful anti-cancer therapies for individuals with ecDNA-driven cancers.

About ecDNA

Extrachromosomal DNA, or ecDNA, are distinct circular units of DNA containing functional genes that are located outside cells chromosomes and can make many copies of themselves. ecDNA rapidly replicate within cancer cells, causing high numbers of oncogene copies, a trait that can be passed to daughter cells in asymmetric ways during cell division. Cancer cells have the ability to upregulate or downregulate oncogenes located on ecDNA to ensure survival under selective pressures, including chemotherapy, targeted therapy, immunotherapy, or radiation, making ecDNA one of cancer cells primary mechanisms of recurrence and treatment resistance. ecDNA are rarely seen in healthy cells but are found in many solid tumor cancers. They are a key driver of the most aggressive and difficult-to-treat cancers, specifically those characterized by high copy number amplification of oncogenes.

About Boundless Bio

Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

For more information, visit http://www.boundlessbio.com.

Follow us on LinkedIn and Twitter.

About Boundless Bios Spyglass Platform

Boundless Bios Spyglass platform is a comprehensive suite of proprietary ecDNA-driven and pair-matched tumor models along with proprietary imaging and molecular analytical tools that enables Boundlesss researchers to interrogate ecDNA biology to identify a pipeline of novel oncotargets essential to the function of cancer cells that are enabled by ecDNA. The Spyglass platform facilitates Boundless innovation in the development of precision therapeutics specifically targeting ecDNA-driven tumors, thereby enabling selective treatments for patients whose tumor genetic profiles make them most likely to benefit from our novel therapeutic candidates.

Original post:
Boundless Bio Announces Publication in Nature Genetics Detailing the Association Between Extrachromosomal DNA-Based Oncogene Amplification and Poor...

How Effective Are Neck Gaiters in Stopping COVID-19 Spread? – Healthline

Neck gaiters can provide a comfortable and stylish way for people to cover their faces during the COVID-19 pandemic.

But that doesnt mean they are effectively protecting against the spread of the novel coronavirus.

In a new study from Duke University in North Carolina, researchers concluded that fleece neck gaiters made from a polyester and spandex blend arent effective in blocking coronavirus droplets.

These respiratory droplets are transmitted when we talk, cough, sing, sneeze, and yawn, say experts.

Since they didnt test other types, the researchers say we shouldnt apply these findings to all neck gaiters on the market.

Experts agree.

There is nothing wrong with neck gaiters being used as face coverings, said Dr. Mitchell H. Grayson, the director of the Division of Allergy and Immunology at Nationwide Childrens Hospital in Ohio.

Grayson is also a tenured professor at The Ohio State University School of Medicine in the Department of Pediatrics, Division of Allergy and Immunology, as well as a fellow of the American Academy of Allergy, Asthma and Immunology.

The problem is the material of which they are made, he told Healthline.

I wear a neck gaiter, but its not made out of polyester, said Ravina Kullar, PharmD, MPH, FIDSA, a leading expert in infectious diseases.

Its made out of cotton and its triple layered as well. So thats the material that would be effective, Kullar told Healthline.

She added that whichever face covering you choose, it should fit your nose and be snug under your chin.

For Grayson, an important issue is making sure you cant see daylight through the mask when you hold it up to light.

I recommend a material that does not have a large enough space between the fibers to allow virus particles to easily pass through, he said.

If you do see daylight, then it is likely that the mask will not perform well in preventing viral spread.

He added, In most cases, a cloth (cotton) mask with several layers is fine, as are surgical/procedure masks, if you can get them.

Grayson also noted that N95 masks with valves arent acceptable. These masks only protect the wearer, and the virus will be expelled through the valve.

However, he said he doesnt believe that all valve-containing masks are a problem. Again, it comes down to the specifics of each type.

There are some cotton masks with multiple cotton layers (and even a removable P2.5 filter) that have a valve attached to the outside layer of fabric, Grayson said.

In most of these Ive seen the valve doesnt actually work (if you exhale strongly while wearing the mask, the air doesnt go out the valve, it just comes out around the mask), he added.

Since any air that would come out of the valve would have gone through all of the layers of fabric, the likelihood of the virus escaping through the valve is minimal (beyond what would normally escape through the fabric).

But in general, Grayson advises avoiding valve-containing masks.

Kullar said its clear some people are forgetting that we are still in a health crisis.

But the coronavirus doesnt care about pandemic fatigue.

There have been so many reports that people have had mass gatherings, and have not had [safety] measures in place, and there have been outbreaks, she said. Do not have mass gatherings.

Kullar defines a mass gathering as any more than 10 people.

And keep that physical distance, she added.

Kullar noted a recent study from the University of Florida showed virus particles can travel as far as 7 to 16 feet.

This is beyond the 6 feet of physical distancing currently recommended by the Centers for Disease Control and Prevention (CDC).

And with wind, the particles might travel, and it might cause the particles to travel toward you, and it might also cause the particles to potentially be spread a lot farther than in the indoor setting, said Kullar.

This means safety precautions are necessary even in outdoor settings.

Grayson mentioned the same study, adding that whenever he is outdoors, he either avoids physical interactions within 20 feet or wears a face covering.

This may be overkill, and 6 feet is probably sufficient. But there is some data suggesting the ability for droplets to travel farther, so Im extra cautious, he said.

I view this as being kind to others. If there is a chance my droplets might be inhaled by them, I will wear a mask to lessen that chance, Grayson added.

Finally, Kullar says you need to wash your face coverings daily with warm water and soap or put them in the washer and dryer.

Also, how you are removing and putting on the mask is just as important, says Kullar. You need to make sure you wash your hands before you do that and make sure you know its clean hands youre removing it with.

View post:
How Effective Are Neck Gaiters in Stopping COVID-19 Spread? - Healthline

COVID-19 Symptoms at the Onset Differ From Symptoms of Seasonal Allergies – PR Web

This study tells us that the individuals with seasonal allergies are very familiar with their symptoms and when prompted, were able to distinguish between them and similar COVID-19 symptoms. - Fabio Ferreli, MD

MILWAUKEE (PRWEB) August 17, 2020

According to a study published in The Journal of Allergy and Clinical Immunology: In Practice (JACI: In Practice), symptoms of Allergic Rhinoconjunctivitis (ARC) differ from nasal and ocular symptoms at the onset of COVID-19. The ability to distinguish between the two will make it easier for those with seasonal allergies to correctly interpret symptoms of both diseases.

Both nasal and ocular symptoms are included as potential signs of COVID-19, which has caused confusion for people suffering from ARC. Patients with documented ARC who were diagnosed with COVID-19 in March 2020 at an academic hospital in Italy were included in the study. A total of 22 patients met inclusion criteria.

Sinonasal and ocular symptoms that were reported in the two weeks before a COVID-19 diagnosis were studied using the Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ). The questionnaire evaluated 14 signs and symptoms on a scale from 0 (not troubled) to 6 (extremely troubled), with score totals ranging from zero to 84 once all question responses were combined. MiniRQLQ was then used to assess patients with ARC by asking them to report their last allergic symptom period before the COVID-19 outbreak. They were asked to compare COVID-19 symptoms and ARC symptoms by defining them as identical, similar, different, or completely different.

The median MiniRQLQ score was 39.5 for the criteria of last allergic symptom period before the COVID-19 outbreak and 15 for the onset of COVID-19. Symptoms of ARC compared to symptoms of COVID-19 at the onset were defined as completely different by 68.2% of patients, different by 13.6%, and similar by 18.2% of patients. None of the patients reported the symptoms as identical.

This study tells us that the individuals with seasonal allergies are very familiar with their symptoms and when prompted, were able to distinguish between them and similar COVID-19 symptoms, said first author Fabio Ferreli, MD. While we realize our study had a rather small sample size, we hope this will reassure allergy sufferers who are attempting to distinguish between COVID-19 and their seasonal allergies.

You can learn more about allergic rhinitis on the American Academy of Allergy, Asthma & Immunology website, aaaai.org.

The American Academy of Allergy, Asthma & Immunology (AAAAI) represents allergists, asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic and immunologic diseases. Established in 1943, the AAAAI has more than 7,100 members in the United States, Canada and 72 other countries. The AAAAIs Find an Allergist/Immunologist service is a trusted resource to help you find a specialist close to home.

Share article on social media or email:

See the rest here:
COVID-19 Symptoms at the Onset Differ From Symptoms of Seasonal Allergies - PR Web